171 related articles for article (PubMed ID: 2533949)
21. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
22. Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
Brueggemeier RW; Li PK
Cancer Res; 1988 Dec; 48(23):6808-10. PubMed ID: 3141048
[TBL] [Abstract][Full Text] [Related]
23. Recent progress in development of aromatase inhibitors.
Santen RJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1029-35. PubMed ID: 2149503
[TBL] [Abstract][Full Text] [Related]
24. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Yue W; Wang J; Savinov A; Brodie A
Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
[TBL] [Abstract][Full Text] [Related]
25. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
26. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
Häusler A; Schenkel L; Krähenbühl C; Monnet G; Bhatnagar AS
J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
[TBL] [Abstract][Full Text] [Related]
27. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
el Etreby MF; Nishino Y; Habenicht UF; Henderson D
J Androl; 1991; 12(6):403-14. PubMed ID: 1722797
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats.
Zaccheo T; Giudici D; Di Salle E
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):677-80. PubMed ID: 8476783
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
30. Effect of an aromatase inhibitor, 1,4,6-androstatriene-3,17-dione, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat and its mechanism of action in vivo.
Brodie AM; Brodie HJ; Garrett WM; Hendrickson JR; Marsh DA; Tsai-Morris CH
Biochem Pharmacol; 1982 Jun; 31(11):2017-23. PubMed ID: 6810900
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.
Zimniski SJ; Brandt ME; Covey DF; Puett D
Breast Cancer Res Treat; 1993; 26(1):15-21. PubMed ID: 8400320
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of the aromatase inhibitor FCE 24928 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.
Zaccheo T; di Salle E
Cancer Chemother Pharmacol; 1993; 31(4):308-12. PubMed ID: 8422695
[TBL] [Abstract][Full Text] [Related]
34. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
35. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
Wing LY; Garrett WM; Brodie AM
Cancer Res; 1985 Jun; 45(6):2425-8. PubMed ID: 3921242
[TBL] [Abstract][Full Text] [Related]
36. Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors--role of aromatase.
Dauvois S; Labrie F
Breast Cancer Res Treat; 1989 Jan; 13(1):61-9. PubMed ID: 2495831
[TBL] [Abstract][Full Text] [Related]
37. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity.
Cos S; González A; Güezmes A; Mediavilla MD; Martínez-Campa C; Alonso-González C; Sánchez-Barceló EJ
Int J Cancer; 2006 Jan; 118(2):274-8. PubMed ID: 16080194
[TBL] [Abstract][Full Text] [Related]
38. Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors.
Spinola PG; Marchetti B; Mérand Y; Bélanger A; Labrie F
Breast Cancer Res Treat; 1988 Dec; 12(3):287-96. PubMed ID: 3147727
[TBL] [Abstract][Full Text] [Related]
39. Anti-androgen effects of the aromatase inhibitor, atamestane.
Shao TC; Marcelli M; Kong A; Cunningham GR
J Androl; 1995; 16(2):100-7. PubMed ID: 7559139
[TBL] [Abstract][Full Text] [Related]
40. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Pérez N; Borja J
J Int Med Res; 1992 Aug; 20(4):303-12. PubMed ID: 1387368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
